Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease

Site 112, Gilbert, Arizona, United States

Site 130, Phoenix, Arizona, United States

Site 121, La Mesa, California, United States

Site 125, Orange, California, United States

Site 103, Sacramento, California, United States

Site 111, San Francisco, California, United States

Site 105, Torrance, California, United States

Site 109, Miami Lakes, Florida, United States

Site 115, Palm Harbor, Florida, United States

Site 123, Sarasota, Florida, United States

Site 118, Macon, Georgia, United States

Site 122, Bowling Green, Kentucky, United States

Site 126, Flint, Michigan, United States

Site 107, Livonia, Michigan, United States

Site 108, Omaha, Nebraska, United States

Site 129, Niagara Falls, New York, United States

Site 120, Orchard Park, New York, United States

Site 104, Columbus, Ohio, United States

Site 124, Sayre, Pennsylvania, United States

Site 100, Amarillo, Texas, United States

Site 117, Conroe, Texas, United States

Site 128, Edinburg, Texas, United States

Site 127, El Paso, Texas, United States

Site 106, Fort Worth, Texas, United States

Site 110, Houston, Texas, United States

Site 101, Humble, Texas, United States

Site 116, San Antonio, Texas, United States

Site 119, Chesapeake, Virginia, United States

Site 151, East Melbourne, Victoria, Australia

Site 150, Melbourne N., Victoria, Australia